RSS   Newsletter   Contact   Advertise with us

Clinigen Group opens office in Tokyo, expands in Japan

Share on Twitter Share on LinkedIn
Staff Writer | October 18, 2016
Clinigen Group, a global pharmaceuticals and services company, has extended its geographical reach to Japan with the opening of a new office in Tokyo.
Clinigen Group
Expansion   Foscavir treats cytomegalovirus
Clinigen KK further expands the group's presence in Asia following the company's acquisition of Link healthcare in 2015.

Its presence in the region will also allow the firm to take over the marketing authorisation for its lead specialty pharmaceutical (SP) product Foscavir from Nobel Pharma, who has distributed the product in Japan for the company since 2011.

Foscavir treats cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) or Cytomegalovirus viremia and cytomegalovirus disease in hematopoietic stem cell transplant (HSCT) patients.

With more than 2,000 patients are treated annually with the drug, Japan is an important market for the firm. The region is also the second largest pharmaceutical market in the world.